3月21日 - ** 生物技术公司CSL的CSL.AX股价下跌0.7
** 摩根士丹利预计上半年流感疫苗销量将下降15%，并指出美国15至64岁人群疫苗接种率下降是导致美国疫苗销量下滑的关键因素
** 经纪公司强调，美国疾病控制与预防中心（CDC）已将2024-25年列为所有年龄段的高危流感季节——这是自2017-18年以来首次
** 尽管目前销量下降，摩根士丹利认为，当前季节的严重程度可能会支持提高下一季节的疫苗接种率
** 给予“增持”评级，目标价为313澳元/股
** 包括当前交易时段在内，年初至今股价下跌9.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.